PLAU — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Hydrochloric Acid (SCHEMBL250043)	0.51	19/20
Amiloride (SCHEMBL27563)	1.00	11/20
Amiloride (SCHEMBL136682)	0.93	11/20
Nafamostat (SCHEMBL135503)	0.57	10/20
SCHEMBL68931	0.67	7/20
SCHEMBL163011	0.55	7/20
SCHEMBL166140	1.00	6/20
SCHEMBL164098	0.56	6/20
SCHEMBL56921	0.46	6/20
SCHEMBL221369	0.60	5/20
SCHEMBL259	0.54	5/20
SCHEMBL132263	0.54	5/20
SCHEMBL247052	0.52	5/20
Hydroxystilbamidine (SCHEMBL108492)	0.51	5/20
SCHEMBL135362	0.60	4/20
SCHEMBL514	0.59	4/20
Stilbamidine (SCHEMBL208655)	0.58	4/20
SCHEMBL49594	0.56	4/20
SCHEMBL220311	0.52	4/20
SCHEMBL220038	0.52	4/20

Clinical trials — most relevant to PLAU by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
12-h and 2-h Urokinase Regimes of Pulmonary Thromboembolism in China	PHASE4	COMPLETED
Does a Single Steroid Injection Reduce the Formation of Postmastectomy Seroma	PHASE4	UNKNOWN
Role Of Different Prophylactic Doses Of Intravenous Tranexamic Acid In Reducing Blood Loss At Caesarean Section	PHASE4	COMPLETED
Study of rhPro-UK in Patients With Acute Ischaemic Stroke in 4.5 Hours After Stroke Onset(PROST)	PHASE3	COMPLETED
Study of Alfimeprase to Rapidly Dissolve Blood Clots in the Leg and Help Prevent the Need for Surgery on Leg Arteries	PHASE3	COMPLETED
Pharmacoinvasive Therapy With Prourokinase	PHASE2/PHASE3	COMPLETED
BEnefits of Stroke Treatment Delivered Using a Mobile Stroke Unit	PHASE2/PHASE3	UNKNOWN
Thrombolysis of Urokinase for Minor Stroke	PHASE3	COMPLETED
Efficacy/Safety of Human Plasminogen Eye Drop in Ligneous Conjunctivitis Patients	PHASE2/PHASE3	COMPLETED
Sonothrombolysis Potentiated by Microbubbles for Acute Ischemic Stroke	PHASE2	COMPLETED
Interventional Management of Stroke (IMS) II Study	PHASE2	COMPLETED
Injection of Recombinant Human Tissue-type Plasminogen Activator Derivative for Acute Pulmonary Embolism(rPA)	PHASE2	UNKNOWN
Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection	PHASE2	COMPLETED
The Effects of DLBS1033 on Haemostasis Parameters in Healthy Volunteers	PHASE2	COMPLETED
Repeated Intravenous Thrombolysis for Ischemic Stroke With Medium to Large Vessel Occlusion Presenting Within 4.5 Hours of Onset With Prourokinase	PHASE2	NOT_YET_RECRUITING
SELESTIAL: Trial of Insulin to Control Blood Sugar After Acute Stroke Using Magnetic Resonance Imaging (MRI) End-Points	PHASE2	COMPLETED
Intra-arterial Thrombolysis for Severe Recent Central Retinal Vein Occlusion	PHASE1	COMPLETED
Assessment of the Soluble Urokinase Plasminogen Activator Receptor in Non-cardiac Surgery (SPARSE)	nan	COMPLETED
SuPAR in Adult Patients With Covid-19	nan	COMPLETED
Disorders of the Acute Phase Response Following Trauma and Invasive Surgery	nan	ENROLLING_BY_INVITATION
Urokinase Plasminogen Activator System in Benign Prostatic Hyperplasia	nan	COMPLETED
Dietary Seaweed and Early Breast Cancer: A Randomized Trial	nan	COMPLETED
Hemospec Device for the Diagnosis of Sepsis	nan	COMPLETED
PiA: Prognosis Used Every Day for Patients With Operable Breast Cancer - Comparison of Invasion Factors uPA/PAI-1 With Other Prognostic Factors	nan	UNKNOWN
Treatment of Acute Ischemic StroKe With Intravenous UroKinase Real-world Research: a Multicenter, Prospective Study	nan	RECRUITING
Intravenous Thrombolysis Registry for Acute Ischemic Stroke in China	nan	WITHDRAWN
Peripheral Vascular Disease and Nerve Stimulation	nan	COMPLETED
Genetic Architecture of Plasma T-PA and PAI-1	nan	COMPLETED
Risk Stratification in Acute Care: The Meaning of suPAR Measurement in Triage	nan	COMPLETED
A Lifestyle Intervention to Improve in Vitro Fertilization Results	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a PLAU binder may also engage these)

Protein	Name	Similarity
P49150	—	1.000	P49150 →
Q8MHY7	—	1.000	Q8MHY7 →
P04185	—	1.000	P04185 →
P16227	—	1.000	P16227 →
Q5RF29	—	1.000	Q5RF29 →
Q5E9Z2	—	1.000	Q5E9Z2 →
P29598	—	1.000	P29598 →
P15638	—	0.999	P15638 →
Q05589	—	0.998	Q05589 →
Q08048	—	0.998	Q08048 →
Q6L711	—	0.996	Q6L711 →
P19637	—	0.996	P19637 →
P11214	—	0.996	P11214 →
P06869	—	0.996	P06869 →
Q58L94	—	0.995	Q58L94 →
Q8SQ23	—	0.995	Q8SQ23 →
P98121	—	0.994	P98121 →
F10	Coagulation factor X	0.994	landscape →
Q7RTY8	—	0.994	Q7RTY8 →
Q58L95	—	0.994	Q58L95 →
P70375	—	0.993	P70375 →
P98119	—	0.993	P98119 →
Q5R8J0	—	0.992	Q5R8J0 →
Q58L96	—	0.992	Q58L96 →
P86091	—	0.992	P86091 →
Q8BZ10	—	0.992	Q8BZ10 →
Q6ZMR5	—	0.992	Q6ZMR5 →
F9	Coagulation factor IX	0.992	landscape →
P14272	—	0.992	P14272 →
Q2F9P2	—	0.991	Q2F9P2 →